CBER’s Goal To Reach Normal Ops In 2023 Includes Clearing IND, Meeting Backlogs In 2022

CBER director Peter Marks also wants to work on rare disease gene therapy issues and increase hiring before the end of the year.

backlog and stacks of paper
CBER wants to reduce the IND backlog in its Office of Vaccines Research and Review before the start of 2023. • Source: Shutterstock

The return to normal operations within the US Food and Drug Administration'sCenter for Biologics Evaluation and Research next year will require eliminating backlogs and resuming regular meeting schedules.

CBER director Peter Marks said the center’s theme for the remainder of 2022 is response and recovery as it tries...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Rare Diseases

More from Pink Sheet